Citrulline decreases hepatic endotoxin-induced injury in fructose-induced non-alcoholic liver disease: an ex vivo study in the isolated perfused rat liver

Wassila Ouelaa1, Prasanthi Jegatheesan1, Japhète M'bouyou-Boungou1, Christelle Vicente1, Samir Nakib1,2, Esther Nubret1 and Jean-Pascal De Bandt1,2*

1EA4466, Faculty of Pharmacy, Paris Descartes University, Sorbonne Paris Cité, 75006 Paris, France
2Clinical Chemistry Department, Hôpitaux Universitaires Paris Centre, Assistance Publique Hopitaux de Paris, 75014 Paris, France

(Submitted 13 January 2017 – Final revision received 12 May 2017 – Accepted 22 May 2017 – First published online 22 June 2017)

Abstract
Steatosis can sensitize the liver to various challenges and favour the development of non-alcoholic fatty liver disease (NAFLD). In this context, fructose feeding promotes endotoxin translocation from the gut, contributing to disease progression via an inflammatory process. Citrulline is protective against fructose-induced NAFLD; we hypothesised that this property might be related to its anti-inflammatory and antioxidative action against endotoxin-induced hepatic injuries. This hypothesis was evaluated in a model of perfused liver isolated from NAFLD rats. Male Sprague–Dawley rats (n 30) were fed either a standard rodent chow or a 60 % fructose diet alone, or supplemented with citrulline (1 g/kg per d) for 4 weeks. After an evaluation of their metabolic status, fasted rats received an intraperitoneal injection of lipopolysaccharide (LPS) (2·5 mg/kg). After 1 h, the livers were isolated and perfused for 1 h to study liver function and metabolism, inflammation and oxidative status. In vivo, citrulline significantly decreased dyslipidaemia induced by a high-fructose diet and insulin resistance. In the isolated perfused rat livers, endotoxaemia resulted in higher cytolysis (alanine aminotransferase release) and higher inductin status.

Key words: Non-alcoholic fatty liver disease: Fructose: Lipopolysaccharide: Isolated perfused liver: Citrulline

Non-alcoholic fatty liver diseases (NAFLD) are hepatic manifestations of the metabolic syndrome(3,4), and represent a major public health issue, affecting about 30 % of the general population in the USA. NAFLD encompasses a wide range of diseases, all initiated by an abnormal accumulation of lipids in the liver – that is, hepatic steatosis. This accumulation can be worsened by an increase in free fatty acid and endotoxin levels in the plasma, which activate Toll-like receptors (TLR) and induce, via the NF-κB signalling pathway, the production of pro-inflammatory cytokines (IL-6 and TNFα), which in turn exacerbate inflammation(2-4). From a mechanistic point of view, in addition to the excess energy intake, dietary factors such as excessive consumption of fructose-enriched products(5) and high-fat diets(6) can act on the liver, with the induction of de novo lipogenesis(7,8) and insulin resistance, and also on the intestine, with increased intestinal permeability and plasma endotoxin levels(2). Endotoxin translocation, and the inflammatory process it induces, can play a major role in the progression from a simple reversible steatosis to NAFLD and non-alcoholic steatohepatitis (NASH)(9,10).

Although the role of massive endotoxin translocation from the intestinal lumen into the bloodstream is well known as a trigger of the inflammatory response in sepsis, an increasing number of studies highlight the existence of a low-grade endotoxin translocation in a number of metabolic disorders(11). This translocation can be induced or amplified by various factors such as diet (fructose, high-fat diet, etc.) or even by slight alterations in intestinal trophicity. At the whole-body level, this has several consequences, starting with a chronic inflammatory condition contributing to alterations in insulin sensitivity. The liver, as the first organ exposed to these endotoxins via the portal vein, can be the target of inflammatory and oxidative stress leading, for example, to endoplasmic reticulum stress and worsening hepatic damage, with ensuing hepatic dysfunction (NAFLD) and subsequent inflammation and fibrosis (NASH).

Abbreviations: AA, amino acid; ALT, alanine aminotransferase; Arg, arginine; C, control; Cit, citrulline; HF, high fructose; HFC, high fructose+citrulline; LPS, lipopolysaccharide; NAFLD, non-alcoholic fatty liver disease; NO, nitric oxide.

* Corresponding author: Professor J. P. De Bandt, fax +33 1 53 73 99 52, email jean-pascal.de-bandt@parisdescartes.fr
Given the high prevalence of NAFLD and its possible evolution, with a significant frequency, towards cirrhosis and hepatocellular carcinoma, the development of strategies to counter this process has become a public health issue. Protection of the liver against stress due to an endotoxin-induced inflammatory process could thus be a new therapeutic target. We set out to assess whether citrulline (Cit) supplementation in the diet could be a useful strategy for this purpose. Indeed, acute or chronic Cit administration can limit inflammation and oxidative stress in various organs including the liver\(^{12-13}\). We have shown that Cit administration prevents the development of fructose-induced NAFLD\(^{12}\) and its deterioration into NASH, and also that it is associated with decreased hepatic endoplasmic reticulum stress\(^{15}\).

Our working hypothesis was that, during the initial stages of NAFLD development, hepatic steatosis sensitises the liver to endotoxin-induced injuries, and that this can be prevented by Cit supplementation, by virtue of the anti-inflammatory and antioxidative properties of this amino acid (AA).

The aim of the present study was to evaluate \textit{ex vivo}, using an isolated perfused rat liver model, the consequences of acute \textit{in vivo} exposure to endotoxin in a previously validated model of fructose-induced mild NAFLD\(^{12}\), and the potential protective effect of Cit supplementation in this situation.

**Methods**

**Animals**

In all, thirty male Sprague–Dawley rats weighing 190–220 g (Charles River) were aclimatised at our animal facility for 1 week in temperature-controlled rooms with a 12 h light–12 h dark cycle. They had free access to water and standard rodent chow (UAR A04; SAFE).

For feeding experiments, animals received either standard rodent chow, or a 60 % fructose-enriched diet (U8060; SAFE). The compositions of the diets are given in Table 1.

**Table 1. Composition of the diets*\right**

<table>
<thead>
<tr>
<th>Ingredients (% total weight)</th>
<th>Control†</th>
<th>Fructose†</th>
<th>HFC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Casein</td>
<td>21.5</td>
<td>21.5</td>
<td>21.5</td>
</tr>
<tr>
<td>α-Methionine</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
</tr>
<tr>
<td>Maltdextrin</td>
<td>20</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Maize starch</td>
<td>40</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Fructose</td>
<td>–</td>
<td>60</td>
<td>60</td>
</tr>
<tr>
<td>Soyabean oil</td>
<td>5</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Cellulose</td>
<td>5</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Vitamins‡</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Minerals§</td>
<td>7</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>Citrulline</td>
<td>0</td>
<td>0</td>
<td>0.75</td>
</tr>
</tbody>
</table>

* Control and fructose diets were supplied by SAFE. These diets were prepared from the same sources, except for maltodextrin and starch for the control diet, which were replaced with fructose in the fructose diet.
† Energy content of the diet is 3481 kcal/kg (14565 kJ/kg).
‡ SAFE premix vitamin 200.
§ SAFE premix mineral 205B.

Animal care and experimentation techniques complied with both French and European Community regulations. All procedures were conducted in accordance with the regional ethics committee’s (Comité régional d’éthique pour l’expérimentation animale d’Ile-de-France) guidelines for animal care, and the study protocol was approved by the same committee (registration no. 00737.02).

**Experimental design (Fig. 1)**

The rats (Fig. 1) were randomly assigned to three groups (\(n = 10\) rats/group) to receive, for 4 weeks, a standard rodent chow (control (C)) or a 60 % fructose diet alone (high fructose (HF)) or supplemented with Cit: 1 g/kg per d (high fructose + citrulline (HFC)). The dose of Cit was chosen on the basis of our previous studies\(^{16-18}\). Body weight and food intake were monitored throughout the experiments.

Blood samples were taken 2 days before the end of the 4-week feeding period from the tail vein of fasting animals for metabolic evaluation.

On the last day, after an overnight fast, rats were anaesthetised by isoflurane inhalation (4–5 %, Vetflurane; Virbac Schweiz AG) and received a single SC injection of buprenorphine (100 mg/kg, Temgesic; Reckitt Benckiser). The animals then received an intraperitoneal injection of a non-lethal dose of endotoxin (2.5 mg/kg lipopolysaccharide (LPS) from \textit{Escherichia coli} 0127:B8 serotype; Sigma). After 1 h, the rats were anaesthetised by isoflurane inhalation, and the livers were prepared for \textit{ex vivo} perfusion and isolated.

All experiments were carried out between 08:00 and 13:00 hours.

**Isolated liver perfusion experiments**

The livers were prepared according to our standard procedure as described previously\(^{19-21}\). In brief, immediately after laparotomy, liver ligaments were cut and the bile duct was cannulated. After heparin injection (1000 IU in saline) into the inferior vena cava, a catheter was placed in the portal vein, and the liver was directly perfused with a warm oxygenated perfusion medium at a flow rate of 10 ml/min, isolated and transferred to the perfusion apparatus.

The livers were perfused in a recirculating system via the portal vein at a constant temperature of 37°C and at constant physiological pressure (12 cm H\(_2\)O). The perfusion medium (150 ml) was a Krebs–Henseleit buffer supplemented with 30 g/l albumin, 8.5 mM glucose and 2 mM Ca. The perfusate was maintained at pH 7.4 and oxygenated with an O\(_2\)/CO\(_2\) mixture (95 %/5 %). At the beginning of the perfusion (\(t = 0\)), the perfusate was supplemented with an antiproteolytic AA mixture. After a 30-min equilibration period (\(t = 60\)), a complete AA mixture was added, and the perfusion was continued for 30 min.

Perfusate pH, portal ow and bile ow were continuously monitored. Bile was collected in Eppendorf tubes, and bile flow was estimated by gravimetry, assuming a specific mass of 1 g/ml.

During the perfusion, perfusate samples were taken at \(t = 55\), \(t = 45\), and \(t = 60\) to measure aspartate aminotransferase (AST), alanine aminotransferase (ALT) and lactate dehydrogenase (LDH) activities, as well as AA, glucose, urea, ammonia and nitrite/nitrate concentrations.
At the end of the perfusion, the livers were weighed on an electronic scale. Samples of the left lobe were immediately frozen in liquid N$_2$.

**Sample treatment**

Blood samples were collected in heparinised tubes. After centrifugation at 5000 g for 10 min at 4°C, plasma was separated and stored at −20°C until analysis. For the measurement of plasma AA, samples were immediately deproteinised with 30 % sulfosalicylic acid (1:10, v/v) and centrifuged. The supernatants were stored at −80°C.

Perfusate samples were frozen immediately, or after sulfosalicylic acid deproteinisation, and stored at −80°C.

**Metabolic evaluation of animals**

Plasma concentrations of cholesterol, TAG, urea and glucose, as well as plasma activity of ALT and AST were determined using standard techniques on a multiparameter analyser (Cobas C 6000; Roche).

Plasma insulin concentration was measured with a rat-specific ELISA kit (Rat Ultrasensitive Insulin ELISA; ALPCO Diagnostic) using the manufacturer’s protocol. Insulin sensitivity was evaluated using the homeostasis model assessment of insulin resistance: (fasting insulin (mU/l) × fasting glucose (mM))/22.

Plasma AA were separated and quantified using ion-exchange chromatography with postcolumn ninhydrin detection using a JLC-500/V AminoTac™ amino acid analyser (Jeol Ltd).

**Liver metabolism**

Perfusate concentrations of urea, ammonia, glucose and AA, as well as plasma activity of ALT, AST and LDH were measured as described above.

**Hepatic lipids**

For the determination of hepatic TAG content, frozen liver samples (100 mg) were homogenised in 5 % NP-40 to extract lipids. The TAG content was evaluated using a commercially available TAG Quantification Kit (Abcam).

**Liver inflammatory and oxidative status**

Total RNA from liver samples was isolated using the TRIzol reagent (Invitrogen), and complementary DNA was synthesised using the Quantitect Rev.Transcription kit (Qiagen). Real-time PCR was performed using the Quantitect SYBER Green PCR kit (Qiagen) according to the manufacturer's instructions. To control for variations in the reactions, all PCR data were normalised to β-actin expression. PCR primers for Tlr4 were F: 5'-ATTCTGGTGTAGCATTGCT-3', R: 5'-ACCACCCACATTA ACTTTCGGG-3'. The comparative cycle threshold method was used to quantify the target gene expression, normalised to an endogenous reference gene and relative to a calibrator ($2^{-\Delta\Delta C_t}$).

Nitric oxide (NO) production was evaluated by the measurement of nitrates + nitrates in the perfusate using the Total Nitric Oxide and Nitrate/Nitrite Assay kit (R&D Systems) after centrifugation of the perfusate samples on a microfilter (Microcon-10kDa Centrifugal Filter Unit; Millipore).

For the measurement of hepatic antioxidative defenses, the liver samples were homogenised in ten volumes of 10 % TCA-5mM EDTA buffer, with an Ultra Turrax homogeniser (Ika Labortechnik). GSH and GSSG in the supernatant were assayed using reverse-phase HPLC coupled to MS. For vitamin A and vitamin E assays, liver samples were ground in liquid N$_2$. The vitamins were assayed, after hexane extraction, using reverse-phase HPLC and spectrophotometric detection.

Liver oxidative status was evaluated by measuring 4-hydroxynonenal (4HNE) protein adducts in the liver homogenate using an Oxiselect HNE Adduct Competitive ELISA kit (Cell Biolabs Inc.) according to the manufacturer's protocol. Hepatic protein content was measured in liver homogenates using a Biorad DC protein assay.

**Calculation and statistics**

Substrate exchanges ($F$) during perfusion were calculated as follows:

$$F = \frac{(C_1 V_1 - C_2 V_2)/((t_1 - t_2) \times W)}{W}.$$  

where $C_1$ and $C_2$ are the concentrations of a given substrate at times $t_1$ and $t_2$ in two successive samples of perfusate, and $V_1$ and $V_2$ the perfuse volumes at the same times, $t_1$ and $t_2$. This formula takes into account variations in perfuse volume throughout the experiment due to evaporation (0.2 ml/min) and sampling. W is
the liver wet weight. The different changes over the whole perfusion period were calculated as the mean of successive values corrected for time. Positive values indicate release of the substrate by the liver, negative values indicate uptake.

Data are presented as means with their standard errors. Prism 6.0 (GraphPad Software) was used for data analysis. Comparison between the groups was performed using a one-way ANOVA with a Fisher post hoc test. The level of statistical significance was set at \( P \leq 0.05 \).

**Results**

**Nutritional and metabolic status**

Plasma TAG and cholesterol concentrations were significantly higher only in the animals fed the HF diet alone, compared with the C group animals. Cit tended to decrease fructose-induced hypertriglycerolaemia (~31%), and significantly decreased the plasma cholesterol concentration \((P < 0.05)\), compared with the HF group (Table 2).

Plasma glucose was significantly higher in the HF and HFC groups, but differences in plasma insulin were not statistically significant, owing to large inter-individual variations. However, the HF diet, when given alone, significantly decreased insulin sensitivity; this was attenuated by Cit (Table 2).

Plasma urea and uric acid levels did not differ between the three groups (Table 2). The HF diet alone resulted in limited changes in plasma AA levels. Cit supplementation was associated with significantly higher plasma Cit, ornithine (Orn) and arginine (Arg) levels in the HFC group than in the C and HF groups. The Arg:lysine (Lys) ratio, an important factor for Arg sensitivity; this was attenuated by Cit (Table 2).

The Arg:Lys ratio, an important factor for Arg entry into the cells\(^{(22)}\), was significantly increased in the HFC group compared with the C and HF groups. Global Arg bioavailability (i.e. the ratio of Arg:(Orn+Cit)\(^{(22)}\)) was decreased by the HF diet and restored by Cit, but this decrease did not reach statistical significance (Table 3).

Liver-enzyme activities remained within the normal range in all groups (Table 2).

**Hepatic function and metabolism during endotoxaemia**

After LPS injection, all animals exhibited classic signs of a non-lethal endotoxaemia, with piloerection, prostration and dacyrorrhea.

Gross liver appearance was similar in all three groups. Compared with a reference value of about 4 ml/min per g at a physiological portal pressure of 12 cm H\(_2\)O, portal flow was dramatically increased in all endotoxaemic rats in this study, but was lower in the HFC group than in the C group (C: 10.7 (SEM 0.4) ml/min per g, HF: 10.0 (SEM 0.6) ml/min per g, HFC: 7.7 (SEM 0.5) ml/min per g; HFC vs. C, \( P < 0.05 \)). Bile flow was also higher than the reference value, with no difference between groups (data not shown). At the end of the 60-min perfusion, ALT activity in the perfusate was significantly higher in the HF group than in the C group (C: 19 (SEM 5) UI/l, HF: 34 (SEM 6) UI/l, HFC: 26 (SEM 4) UI/l; HF vs. C, \( P < 0.05 \)). Final liver wet weight was similar between the three groups (C: 12.3 (SEM 0.4) g, HF: 13.0 (SEM 1.0) g, HFC: 14.5 (SEM 0.9) g; NS).

In terms of global metabolism, only slight changes were observed because of large inter-individual variations (Table 4), with slightly lower urea production and higher ammonia and glucose release in the HF group compared with glucose uptake in the other two groups. The increase in hepatic TAG content in the HF group did not reach statistical significance.

AA fluxes (Table 5) were similar between the three groups.

**Hepatic inflammation and oxidative stress (Table 6)**

As regards LPS-induced (Table 6) hepatic inflammation, fructose feeding tended to increase Tlr4 gene expression \((P = 0.084)\), but did not affect NO production. In the Cit-supplemented group, NO production and Tlr4 expression were similar to those in the C group (Fig. 2).

**Table 2. Effect of fructose diet and citrulline on nutritional and metabolic status investigated at the end of the feeding period 2 d before euthanasia** (Mean values with their standard errors; \( n = 10 \) per group)

<table>
<thead>
<tr>
<th></th>
<th>C</th>
<th>SEM</th>
<th>Mean</th>
<th>SEM</th>
<th>Mean</th>
<th>SEM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body weight (g)</td>
<td>348</td>
<td>4</td>
<td>324</td>
<td>7</td>
<td>364</td>
<td>8</td>
</tr>
<tr>
<td>Glucose (mmol/l)</td>
<td>9.4</td>
<td>0.7</td>
<td>12.0*</td>
<td>0.7</td>
<td>12.1*</td>
<td>0.7</td>
</tr>
<tr>
<td>Insulin (µg/l)</td>
<td>1.0</td>
<td>0.2</td>
<td>1.2</td>
<td>0.2</td>
<td>1.0</td>
<td>0.2</td>
</tr>
<tr>
<td>TAG (mmol/l)</td>
<td>1.2</td>
<td>0.3</td>
<td>2.4*</td>
<td>0.4</td>
<td>1.9</td>
<td>0.2</td>
</tr>
<tr>
<td>Cholesterol (mmol/l)</td>
<td>1.4</td>
<td>0.1</td>
<td>1.8*</td>
<td>0.1</td>
<td>1.5†</td>
<td>0.1</td>
</tr>
<tr>
<td>Urea (mmol/l)</td>
<td>3.9</td>
<td>0.4</td>
<td>4.4</td>
<td>0.4</td>
<td>4.6</td>
<td>0.3</td>
</tr>
<tr>
<td>Uric acid (µmol/l)</td>
<td>31</td>
<td>5</td>
<td>23</td>
<td>3</td>
<td>27</td>
<td>4</td>
</tr>
<tr>
<td>AST (UI/l)</td>
<td>67</td>
<td>4</td>
<td>54*</td>
<td>2</td>
<td>60</td>
<td>4</td>
</tr>
<tr>
<td>ALT (UI/l)</td>
<td>28</td>
<td>2</td>
<td>32</td>
<td>2</td>
<td>33</td>
<td>3</td>
</tr>
<tr>
<td>ALP (UI/l)</td>
<td>131</td>
<td>19</td>
<td>169*</td>
<td>6</td>
<td>164</td>
<td>10</td>
</tr>
</tbody>
</table>

* Mean value was significantly different from the C group \((P < 0.05)\).
† Mean value was significantly different from the HF group \((P < 0.05)\).

**Table 3. Effects of citrulline on plasma amino acids related to arginine availability in fructose-fed rats†** (Mean values with their standard errors; \( n = 10 \) per group)

<table>
<thead>
<tr>
<th></th>
<th>C</th>
<th>SEM</th>
<th>Mean</th>
<th>SEM</th>
<th>Mean</th>
<th>SEM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cit</td>
<td>94</td>
<td>11</td>
<td>85</td>
<td>3</td>
<td>136†</td>
<td>12</td>
</tr>
<tr>
<td>Arg</td>
<td>169</td>
<td>16</td>
<td>137</td>
<td>10</td>
<td>246†</td>
<td>38</td>
</tr>
<tr>
<td>Orn</td>
<td>54</td>
<td>5</td>
<td>50</td>
<td>2</td>
<td>88†</td>
<td>18</td>
</tr>
<tr>
<td>Lys</td>
<td>717</td>
<td>68</td>
<td>611</td>
<td>41</td>
<td>638</td>
<td>86</td>
</tr>
<tr>
<td>Arg/Lys</td>
<td>0.23</td>
<td>0.01</td>
<td>0.23</td>
<td>0.01</td>
<td>0.38†</td>
<td>0.04</td>
</tr>
<tr>
<td>Arg/(Orn+Ct)</td>
<td>0.24</td>
<td>0.15</td>
<td>0.148</td>
<td>0.05</td>
<td>1.20</td>
<td>0.09</td>
</tr>
</tbody>
</table>

C, control; HF, high fructose; HFC, high fructose + citrulline.
* Mean value was significantly different from the C group \((P < 0.05)\).
† Mean value was significantly different from the HF group \((P < 0.05)\).
‡ Amino acid concentrations (µmol/l) in plasma were measured at the end of the feeding period 2 d before euthanasia.
As regards oxidative status, the hepatic content of vitamins A and E, and GSSG/GSH ratio were similar in the three groups. LPS-induced oxidative stress, as evaluated by the hepatic content of 4HNE-protein adducts, was also similar between the three groups.

Discussion

In agreement with our previous studies\(^{12,24}\), our results confirm, in a model of mild NAFLD, that Cit supplementation in the diet improves the metabolic status of fructose-fed rats. Our data further show that in these conditions, hepatic steatosis is associated with increased sensitivity to LPS-induced alterations, compared with conventionally fed rats, and suggest that the preventive effects of Cit on the progression of NAFLD occur via a reduction in LPS-induced inflammation without modifications in oxidant/antioxidant status (Fig. 1).

In line with literature data, feeding a 60% fructose diet to rats is associated with dyslipidaemia and decreased insulin sensitivity, as observed in other fructose-fed rat models\(^{25}\). In another set of experiments\(^{12}\), we showed that 4-week fructose feeding, as used in the present experiments, led to dyslipidaemia and hepatic steatosis with increased hepatic TAG content and microvesicular steatosis. At this stage, hepatic aminotransferases

---

### Table 4. Viability and function of the isolated liver in endotoxaemic fructose-fed rats

<table>
<thead>
<tr>
<th></th>
<th>C</th>
<th>SEM</th>
<th>HF</th>
<th>SEM</th>
<th>HFC</th>
<th>SEM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urea (µmol/min per g)(^{†})</td>
<td>2.3</td>
<td>0.2</td>
<td>2.1</td>
<td>0.5</td>
<td>2.3</td>
<td>0.5</td>
</tr>
<tr>
<td>Glucose (µmol/min per g)(^{†})</td>
<td>-1.7</td>
<td>0.2</td>
<td>0.9</td>
<td>0.2</td>
<td>-4.1</td>
<td>4.7</td>
</tr>
<tr>
<td>Ammonia (nmol/min per g)(^{†})</td>
<td>78</td>
<td>94</td>
<td>218</td>
<td>118</td>
<td>75</td>
<td>116</td>
</tr>
<tr>
<td>Hepatic TAG content (nmol/liver)</td>
<td>436</td>
<td>152</td>
<td>625</td>
<td>139</td>
<td>592</td>
<td>78</td>
</tr>
</tbody>
</table>

C, control; HF, high fructose; HFC, high fructose + citrulline.

\(^{†}\) At the end of the feeding period, livers were isolated from endotoxaemic rats and perfused for 60 min. Hepatic fluxes were calculated from the variations in substrate concentrations in the perfusate between t\(_{0}\) and t\(_{60}\). Statistical analysis did not show any differences between groups.

### Table 5. Hepatic amino acid (AA) fluxes (nmol/min per g) in endotoxaemic fructose-fed rats

<table>
<thead>
<tr>
<th></th>
<th>C</th>
<th>SEM</th>
<th>HF</th>
<th>SEM</th>
<th>HFC</th>
<th>SEM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asp</td>
<td>-3</td>
<td>4</td>
<td>-1</td>
<td>2</td>
<td>-1</td>
<td>4</td>
</tr>
<tr>
<td>Thr</td>
<td>-5</td>
<td>6</td>
<td>-2</td>
<td>4</td>
<td>-6</td>
<td>9</td>
</tr>
<tr>
<td>Ser</td>
<td>-14</td>
<td>4</td>
<td>-7</td>
<td>3</td>
<td>-10</td>
<td>6</td>
</tr>
<tr>
<td>Asn</td>
<td>-15</td>
<td>5</td>
<td>-9</td>
<td>3</td>
<td>-11</td>
<td>5</td>
</tr>
<tr>
<td>Glu</td>
<td>32</td>
<td>7</td>
<td>20</td>
<td>2</td>
<td>15</td>
<td>3</td>
</tr>
<tr>
<td>Gln</td>
<td>-22</td>
<td>15</td>
<td>-22</td>
<td>15</td>
<td>-28</td>
<td>24</td>
</tr>
<tr>
<td>Gly</td>
<td>-9</td>
<td>9</td>
<td>-1</td>
<td>8</td>
<td>-8</td>
<td>6</td>
</tr>
<tr>
<td>Ala</td>
<td>-72</td>
<td>22</td>
<td>-45</td>
<td>18</td>
<td>-35</td>
<td>27</td>
</tr>
<tr>
<td>Cys</td>
<td>-3</td>
<td>1</td>
<td>-2</td>
<td>1</td>
<td>-3</td>
<td>2</td>
</tr>
<tr>
<td>Met</td>
<td>-9</td>
<td>5</td>
<td>-7</td>
<td>2</td>
<td>-7</td>
<td>4</td>
</tr>
<tr>
<td>Phe</td>
<td>-26</td>
<td>7</td>
<td>-15</td>
<td>4</td>
<td>-14</td>
<td>5</td>
</tr>
<tr>
<td>Orn</td>
<td>16</td>
<td>3</td>
<td>18</td>
<td>4</td>
<td>16</td>
<td>4</td>
</tr>
<tr>
<td>His</td>
<td>-7</td>
<td>5</td>
<td>-3</td>
<td>3</td>
<td>-6</td>
<td>6</td>
</tr>
<tr>
<td>Lys</td>
<td>-9</td>
<td>10</td>
<td>-5</td>
<td>5</td>
<td>-8</td>
<td>10</td>
</tr>
<tr>
<td>Arg</td>
<td>-21</td>
<td>4</td>
<td>-16</td>
<td>5</td>
<td>-20</td>
<td>5</td>
</tr>
<tr>
<td>Pro</td>
<td>-24</td>
<td>9</td>
<td>-16</td>
<td>6</td>
<td>-11</td>
<td>8</td>
</tr>
<tr>
<td>TAA</td>
<td>-149</td>
<td>134</td>
<td>-80</td>
<td>77</td>
<td>-181</td>
<td>138</td>
</tr>
<tr>
<td>BCAA</td>
<td>36</td>
<td>30</td>
<td>28</td>
<td>13</td>
<td>-9</td>
<td>36</td>
</tr>
</tbody>
</table>

C, control; HF, high fructose; HFC, high fructose + citrulline; TAA, total amino acid flux; BCAA, branched-chain amino acid (Val + Leu + Ile) flux.

\(^{†}\) At the end of the feeding period, livers were isolated from endotoxaemic rats and perfused for 60 min. AA fluxes were calculated from the variations in AA concentrations in the perfusate between t\(_{0}\) and t\(_{60}\). Negative values indicate uptake, positive ones indicate release. Statistical analysis did not show any differences between groups.

---

### Table 6. Hepatic oxidative status in endotoxaemic fructose-fed rats

<table>
<thead>
<tr>
<th></th>
<th>C</th>
<th>SEM</th>
<th>HF</th>
<th>SEM</th>
<th>HFC</th>
<th>SEM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamin E (nmol/g)</td>
<td>47.6</td>
<td>2.6</td>
<td>50.0</td>
<td>2.4</td>
<td>49.6</td>
<td>2.0</td>
</tr>
<tr>
<td>Vitamin A (nmol/g)</td>
<td>771</td>
<td>87</td>
<td>827</td>
<td>98</td>
<td>755</td>
<td>34</td>
</tr>
<tr>
<td>GSSG/GSH</td>
<td>2.1</td>
<td>0.3</td>
<td>2.8</td>
<td>0.5</td>
<td>1.9</td>
<td>0.2</td>
</tr>
<tr>
<td>4HNE (µg/mg protein)</td>
<td>10.4</td>
<td>2.0</td>
<td>12.0</td>
<td>2.7</td>
<td>11.4</td>
<td>3.1</td>
</tr>
</tbody>
</table>

C, control; HF, high fructose; HFC, high fructose + citrulline; 4HNE, 4-hydroxynonenal.

\(^{†}\) At the end of the feeding period, livers were isolated from endotoxaemic rats and perfused for 60 min. Hepatic oxidative status was measured at the end of the 60-min perfusion.

---

**Fig. 2.** Hepatic inflammatory status in endotoxaemic fructose-fed rats. At the end of the feeding period with a control or a fructose diet, livers were isolated from endotoxaemic rats and perfused for 60 min. Hepatic inflammatory status was evaluated by liver Tlr\(_4\) gene expression (presented as its ratio to β-actin) at the end of the 60-min perfusion (a) and by nitrates + nitrates concentration in the perfusate (b). C, control; HF, high fructose; HFC, high fructose + citrulline; Tlr\(_4\), Toll-like receptor 4. Values are means (n 6–7 per group), with standard errors represented by vertical bars. * HFC vs. C and HFC (P = 0.084).
remain in the normal range, making it a model of mild NAFLD. As previously described, the present data also show that Cit supplementation has a positive effect on these parameters. Besides specific effects on the liver, as discussed below, the protective effects of Cit may occur via several mechanisms. In vitro studies in various conditions have shown that Cit supplementation is associated with improved muscle protein metabolism, decreased total and visceral fat mass, improved gut-barrier function and prevention of hepatic steatosis. Some of these studies showed a direct effect of Cit on adipocytes via a NO-dependent process, and on muscle cells through PI3K/MAPK/4E-BP1 signalling. Cit supplementation is also associated with improved insulin sensitivity and endothelial function. Interestingly, in the experiments of the present study, Cit supplementation was found to be associated with higher plasma Arg, a trend toward normalisation of the Arg:Orn + Cit ratio – a marker of global Arg availability for NO synthesis – and with a higher Arg:Lys ratio – a marker of Arg entry into the cells. Taking into account the role of NO in the peripheral effects of insulin, the role of NO synthesis from Arg in Cit-related effects needs to be investigated.

We note that the model used in our experiment is one of mild steatosis, compared with other studies from our laboratory. This condition was chosen because hepatic alterations that favour the development and progression of NAFLD are cumulative and may occur before NAFLD is fully established. Given our experimental conditions, it was not possible to determine liver lipid content before perfusion experiments; hepatic steatosis was thus difficult to evaluate in our experiments. Only a slight increase in hepatic lipid content was noted in the HF group at the end of isolated liver perfusion. As hepatic TAG content was measured only at the end of the perfusion experiments, this was probably a consequence of our experimental conditions and the combination of the mildness of our model of steatosis and the ability of endotoxin to induce hepatic TAG release.

Unfortunately, we were unable to determine TAG release precisely during our ex vivo experiments, owing to the too-low TAG concentration in the perfusion medium.

In this context of mild steatosis, fructose feeding tended to increase the susceptibility of the liver to LPS-induced inflammation, and this effect was dampened by Cit supplementation. Moreover, the response to an acute non-lethal endotoxaemia does not seem to be associated with higher hepatic oxidative stress, at least in the short term.

Our experimental conditions were chosen in order to induce transient non-lethal inflammation. Although this dose of LPS is not considered very high, it is eight times higher than that used by Cani et al. to obtain LPS levels similar to those found in metabolic endotoxaemia. However, comparison is difficult because both animal species (rats vs. mice) and modes of administration (intraperitoneal bolus vs. subcutaneous continuous perfusion) differ. We note that in Cani’s study LPS concentration was measured in the peripheral blood; given the role of the liver in endotoxin clearance, it is reasonable to assume that in the postprandial period, LPS level in the portal vein reached notably higher values, but probably not the level used in our experiments. We chose to isolate and perfuse the liver of animals used in our study 1 h after the LPS challenge, taking into account the kinetics of hepatic inflammatory response to LPS, this enabled us to evaluate direct effects of LPS on the liver, largely independent of the systemic response to LPS. Insofar as our aim was to detect possible sensitisation of the liver to endotoxin as a consequence of steatosis, and given the fact that Cit may not suppress – but simply mitigate – the response to LPS, only endotoxaemic rats were evaluated.

As regards liver function, the HF group presented portal and bile flows similar to those in the C group, but showed increased ALT activity in the perfusate. Interestingly, all groups presented a high portal flow rate relative to the applied physiological portal pressure (12 cm H2O). This may be related to the well-known stimulatory effect of LPS on inducible NO synthase and the vasodilatory effects of NO. Increased ALT release in the HF group suggests that fructose feeding is associated with a higher susceptibility to LPS-induced liver injury, consistent with the role of fructose in the development of cellular stress and a hepatic pro-inflammatory state. This pro-inflammatory state is further confirmed by the trend towards higher Tlr4 expression in the same group. This probably explains the few perturbations observed in hepatic metabolism, with lower ureagenesis and higher ammonia release observed in the same group. Changes in AA exchange between groups were not significant, owing to large inter-individual variations. Surprisingly, fructose feeding was not associated with a higher LPS-induced oxidative stress, as demonstrated by similar levels of antioxidative vitamins and 4HNE, a marker of lipid peroxidation. Our data thus suggest that, at least in the initial stages of hepatic steatosis, the development of NAFLD is not a consequence of oxidative stress, but rather of fructose metabolism itself and of endoplasmic reticulum stress. However, although some alterations in hepatic metabolism – for example, in bromosulfophthalein clearance and excretion – have been shown to occur very rapidly after exposure to LPS, we cannot rule out the possibility that other alterations may need more time to develop, a point that deserves further research.

In this setting, Cit prevents the LPS-induced increase in ALT release observed in the HF group and the associated increase in Tlr4 expression, suggesting decreased inflammation. It would have been of interest to measure pro-inflammatory cytokine production to make a fuller investigation of the inflammatory process; NO production was similar between the three groups, but we had previously observed in isolated peritoneal macrophages from Zucker diabetic fatty rats that Cit did not affect NO synthesis, but decreased TNF release. Surprisingly, oxidative stress was not affected by Cit supplementation. This contrasts with previous studies from our group, however, in these studies, oxidative stress was evaluated under conditions of chronic metabolic stress. Moreover, in the experiments of the present study, animals were studied in the fasted state – that is, at least 18 h after the Cit-supplemented diet had been withdrawn. It would be of interest to evaluate the effect of Cit on oxidative status in the postprandial phase.

As regards the mechanisms involved, besides Cit peripheral effects, our in vivo experiments and recent experiments in a hepatocyte cell line indicate that Cit acts directly on the liver. In vivo, we showed that Cit prevents fructose-induced
expression of the transcription factors SREBP1c and CHREBP, key inducers of hepatic de novo lipogenesis, and that it increases the expression of PPARα, favouring fat oxidation. This was associated with decreased endoplasmic reticulum stress and decreased expression of the pro-apoptotic CCAAT/enhancer-binding protein homologous protein (CHOP) protein.15,24 Our in vitro experiments on a model of fructose-induced steatosis in the hepatic H4IIE cell line41 confirmed these observations, supporting the hypothesis of a direct effect of Cit on hepatic endoplasmic reticulum stress.

All these metabolic and liver function data suggest that 4-week fructose feeding is associated with increased liver sensitivity to the inflammatory effect of LPS, but not to LPS-induced oxidative stress. These data do not therefore support the idea of oxidative stress as a major factor contributing to the initiation of NAFLD. In this context, our data show that Cit supplementation reduces LPS-induced liver inflammation, independently of oxidative stress.

Acknowledgements

The authors thank the staff of the animal facility of the Faculty of Pharmacy, Paris Descartes University.

This project was supported by a French National Research Agency (ANR) grant (ANR-11-BSV1-0015, NAFLD-citrulline).

J.-P. D. B. and P. J. designed the study; W. O., P. J., J. M.-B., C. V., S. N., E. N. carried out the experiments and/or the biological assays; J.-P. D. B. and P. J. wrote the manuscript; all authors have read and approved the final manuscript.

Professor J.-P. D. B. is a shareholder of Citrage Company.

References


